Ceva Stock News

Biosimilars Market Overview: Biosimilars are similar to the drugs that previously have been approved. The biosimilars can be manufactured only when the patent for the original product expires, as they are identical copies of the original product. Biosimilars have applications in various

Avian Influenza Vaccines market research report serves a lot of parameters and detailed data about healthcare industry. The report endows with the steadfast knowledge and information of revolutionizing market landscape, what already exists in the market, future trends or what

Nuveen Asset Management LLC decreased its position in shares of CEVA, Inc. (NASDAQ:CEVA) by 6.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,866 shares of the semiconductor companys stock after selling 5,192 shares during the period. Nuveen Asset []

Charles Schwab Investment Management Inc. grew its holdings in shares of CEVA, Inc. (NASDAQ:CEVA) by 3.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 158,006 shares of the semiconductor companys stock after purchasing an additional 4,553 shares during the period. []

Zacks Investment Research lowered shares of CEVA (NASDAQ:CEVA) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning, Zacks.com reports. According to Zacks, CEVA is the leading licensor of signal processing IP for a smarter, connected world. They partner with semiconductor companies and OEMs worldwide to create []

Amalgamated Bank acquired a new position in CEVA, Inc. (NASDAQ:CEVA) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,314 shares of the semiconductor companys stock, valued at approximately $582,000. Amalgamated Bank owned approximately 0.05% of CEVA at the end of the most recent reporting []

Goldman Sachs Group Inc. boosted its stake in shares of CEVA, Inc. (NASDAQ:CEVA) by 33.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 156,476 shares of the semiconductor companys stock after purchasing an additional 39,069 shares during the period. Goldman Sachs Group Inc. owned []

DUBLIN, Nov. 16, 2021 /PRNewswire/ -- The "Global Animal Nutrition Market (2021 Edition)" report has been added to ResearchAndMarkets.com''s offering. The Global Animal Nutrition Market was valued at USD 26.54 billion in the year 2020. The major factors driving the growth of the global

Veterinary Pain Management market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 13.55% in the above-mentioned forecast period. Rise in the

CEVA (NASDAQ:CEVA) and Wix.com (NASDAQ:WIX) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation. Insider and Institutional Ownership 78.9% of CEVA shares are owned by institutional investors. Comparatively, 91.2% of []

CEVA, Inc. (CEVA) CEO Gideon Wertheizer on Q3 2021 Results - Earnings Call Transcript

CEVA Inc (NASDAQ: CEVA) reported third-quarter FY21 revenue growth of 31% year-on-year to $32.8 million, beating the consensus of $31.2 million. Segments: Licensing, non-recurring engineering (NRE

Ceva (CEVA) delivered earnings and revenue surprises of 25.00% and 5.83%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ROCKVILLE, Md., Sept. 30, 2021 /PRNewswire/ -- CEVA, Inc. (NASDAQ: CEVA), the leading licensor of wireless connectivity and smart sensing technologies, together with Beken Corporation, a key player i

CEVA Inc (NASDAQ: CEVA) reported second-quarter FY21 revenue growth of 29% year-on-year to $30.5 million, beating the analyst consensus of $25.4 million. Segments: Licensing, non-recurring enginee